Text Size
Santen Global

2021 Press Release

RSS

Press Release

Santen and Aerie to accelerate global deployment of Rhopressa/Rhokiinsa and Rocklatan/Roclanda Expanding the area of exclusive licensing, including Europe and China
Santen and ActualEyes sign a joint development agreement on Phase II clinical trial (Phase II a / PoC study) for a treatment candidate for Fuchs endothelial corneal dystrophy
Notice of Corporate Officer Appointments
Singapore National Eye Centre and Santen Announce a Strategic Partnership to Develop and Deploy Internationally an Innovative Educational Programme for Development of the Eye Care Ecosystem in Asia
Notice on the Selection to Apply to New Market Segment "Prime Market" on the Tokyo Stock Exchange
Santen and Airdoc Partner to Improve Diagnostic Rate of Fundus Ocular Diseases with AI device in China
Santen Files for Manufacturing and Marketing Approval of STN1008903 (diquafosol sodium) - Improved formulation to reduce the frequency of administration to ease patients' burden -
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101, a novel investigational treatment for progressive childhood myopia
Santen and IAPB taking action to implement the first ever UN General Assembly resolution recognizing the link between eye health and sustainable development
Santen's CO2 emission reduction targets endorsed by the Science Based Targets (SBT) initiative
Santen Receives U.S. FDA Approval for Verkazia (Cyclosporine Ophthalmic Emulsion, 0.1%) for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Santen Announces Medium-Term Plan "MTP2025"
Santen Establishes "Santen Vision for the Earth 2050" Setting Environmental Targets for 2030, Including CO2 Emissions Reduction Targets
Santen expresses a stance to strengthen its gender diversity. -Joining the "30% Club Japan," taking action to increase gender diversity at board and senior management -Becoming a signatory of the "UN Women's Empowerment Principles" promoting gender equali
Santen Reports Fiscal 2020 Consolidated Performance
Notice of Postponement of "Transition to a Holding Company Structure through Sole-share Transfer and Change in Fiscal Year"
Notice of Board of Director and Corporate Auditor Nominations
Santen has commenced the construction of the new factory in Suzhou to address expanding product demand in China -Toward reinforcing global production and supply structure-
Notice of Recording of Impairment Loss and Revision of Full-Year Earnings Forecasts
Notice of Corporate Officer Appointments
Santen Announces Sponsorship of IBSA Blind Football World Grand Prix for the Second Consecutive Year
Notice of Commencement of Preparation for Transition to a Holding Company Structure through Sole-Share Transfer and Change in Fiscal Year
Santen Reports the 3rd Quarter Fiscal 2020 Consolidated Performance
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) (JAN: Omidenepag Isopropyl) as a Treatment for Patients with Glaucoma and Ocular Hypertension
Santen and Ube Announces Launch of Glaucoma and Ocular Hypertension Treatment EYBELIS Ophthalmic Solution 0.002% in South Korea
Santen Joins the Valuable 500 International Initiative Promoting the Active Participation of People with Disabilities
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved